Trial Search Results
Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.
Stanford is currently not accepting patients for this trial.
- Drug: Exendin (9-39)
- Other: Placebo
- Men and women ages 18-65
- BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric
- Acute medical illness, such as acute bacterial or viral syndrome, febrile illness,
acute abdominal symptoms, orthopedic injury within one week
- History of cardiac failure, renal insufficiency (estimated Crcl<30cc/min), hepatic
insufficiency, chronic obstructive pulmonary disease, anemia (Hct<30%), or
uncontrolled hypertension (SBP>160 or DBP>100)
- Use of medications that affect glucose metabolism
- Fasting glucose >150 or HbA1c>7.5 on Metformin
- Women of childbearing potential (will have a pregnancy test, in addition use of
abstinence for at least one month prior to study or use two types of contraceptives,
hormonal implant or Depo Provera)
- Active, uncontrolled psychiatric disease
- Participating in other studies or have received investigational medications within the
past month or 5 half-lives of the drug, whichever is longer.
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study